anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A treatment composition for treating human skin that has one or more particulate suspending agents in a concentration of from about 0.05% to about 2.0%, by weight, and one or more film forming polymers in a concentration of from about 0.1% to about 5.0%, by weight. Further, particles in a concentration of from about 1.0% to about 20.0%, by weight; one or more humectants in a concentration of from about 2.0% to about 20.0%, by weight; and, water are provided. The treatment compositions of this invention are used in an applicator having an applicator head having one or more applicator nozzles which may be in a array. The apparatus further has a reservoir containing the treatment composition, a sensor, and a CPU. The sensor takes an image of at least 10 μm 2  of skin, the CPU analyzes the image to calculate one or more localized L values of individual pixels or group of pixels of the skin. Then the CPU compares the local L value to a predetermined background L value to identify skin deviations. A skin deviation occurs where the difference between the background L value and the local L value is greater than a predetermined ΔL S  value.
Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
The invention relates to a dental retraction composition comprising guanidinyl-containing polymer, carrageenan, filler, paste-forming component, organic acid having a molecular weight of 80 to 250 g/mol, a pks value of 2 to 5, 1 to 3 carboxylic acid moieties, and being soluble in polyethylene glycol with a molecular weight of 400 g/mol, the dental retraction composition not containing water in an amount of more than 5 wt. %, and not containing aluminium chloride in an amount of more than 0.5 wt. %, wt. % with respect to the weight of the dental retraction composition. The dental retraction composition is for use in a process for use in a process of retracting dental tissue in combination with coagulating blood. The invention also relates to a delivery device comprising the dental retraction composition and a kit of parts comprising the delivery device, an applier for the delivery device, optionally a dental impression material, and optionally a retraction cap.
Some nanopartides described herein have at least two compounds, or a reaction produd of them. At least the first compound is in part or entirely bio-based. The second compound is a monomer, oligomer, macromer or polymer containing at least one moiety or functional group not present in the first compound. The nanopartides may be made, for example, prepared by a reactive extrusion process. In on example, nanopartides are made with starch and alkyl polyglycoside (APG), a bio-based surfactant oligomer. In another example, nanopartides are made with starch and maleated alkyl polyglycoside, a bio-based macromer. These nanopartides may be co polymerized with other monomers, for example to produce a latex binder, in a free radical copolymerization process.
Procedures: Patients who underwent unilateral TKA were randomized as Kinesio Taping® group, MLD group and control group. For all patients, postoperative rehabilitation program included early mobilization and physical therapy twice a day during the stay in orthopedic traumatology department. On the second day after surgery, lymphatic correction method was used on the Kinesio Taping® group patients and a standardized 30-minute MLD treatment was applied to the MLD group patients. Control group received only physiotherapy treatment. Circumference measurements were applied on preoperatively and the second, third, fourth day and 6th weeks after surgery. Knee Injury and Osteoarthritis Outcome Score (KOOS) was used to determine the functional outcomes on the 6th weeks after surgery. Repeated measures of variance analysis was used to determine time differences between groups.
Patients with partially edentulous and atrophic jaws, requiring implant-prosthetic rehabilitation (from 1 to 3 implants), classified as Seibert Class II or III, and needing a GBR bone regeneration intervention with defects not exceeding 7 mm in height. Patients must be 18 years or older and must provide informed consent.
Arteriovenous fistula (AVF) is the preferred vascular access for hemodialysed patients. AVF is created surgically using the patient's artery and vein. Once the connection (anastomosis) is made, the maturation process begins. Studies have shown that most AVFs do not survive beyond one year. This study presents fluid-structure interaction (FSI) modelling of non-Newtonian blood flow through an end-to-side radio-cephalic AVF, investigated weekly during a 15-week follow-up period and 1.5 years postoperatively using ultrasound methods. The aim was to collect qualitative and quantitative data regarding changes in hemodynamics and alterations in the walls of AVF vasculature. Different material properties were assigned to the artery, suture zone (anastomosis), and vein, while the stiffening of the venous arm over time was also modelled. The proposed FSI methodology can be implemented in future follow-up studies involving groups of patients. The main findings revealed: a) counter-rotating vortices in the anastomosis cross-section affecting local pressure conditions; b) different temporal progression of vorticity, shear strain rate, and turbulent kinetic energy and similarity of the temporal progression of WSS obtained under the assumptions of the rigid-walled and FSI; c) a negligible low-WSS zone in the presented thrombosis-free AVF; d) migration of the zone of maximal temporal wall deformation over time.
Highly active antiretroviral therapy (HAART) for HIV produces dramatic reductions in morbidity and mortality for many patients who maintain a high level of adherence to their medications. However, 20% to 33% of HIV infected patients will miss at least one of their medication doses over a one to three day period. Patient self-report is the most practical method for assessing adherence, but it may produce unreliable and invalid results unless optimally performed. A computer-assisted, self-administered adherence program could improve HIV infected patients' adherence behaviors by accurately and efficiently assessing their medication adherence, delivering an adherence intervention to patients, and producing adherence reports for providers. By providing a neutral and seemingly private interview, computer programs may increase patient disclosure of non-adherence. This study will evaluate the efficacy of a computer-assisted, self-administered adherence program in reducing regimen misunderstandings and enhancing patient adherence.

Participants in this study will be recruited from within the Positive Health Program at San Francisco General Hospital. Patients will be randomly assigned to a Control or Intervention Group. Control Group participants will complete an audio computer-assisted self-interview (A-CASI) assessing their understanding of their medication regimen and adherence. Intervention Group participants will complete the adherence A-CASI and will receive a brief computer-delivered intervention consisting of a graphical depiction of their correct regimen and strategies for improving adherence. Study investigators will forward a computer-generated adherence report, which summarizes their adherence and suggests appropriate interventions, to the Intervention Group's health care providers. All participants will be assessed at least three times over a 6-month period: study entry, Month 3, and Month 6.
For Arm 3, the investigators will implement the adapted PM+ utilizing the complete manual of operations and adaptation lessons learned in the non-clinical trial portion of the study. The investigators will train mentor mothers to serve as PM+ Helpers. In the mHealth delivered version of PM+, PM+ Helpers will conduct PM+ virtually after an initial meeting to create rapport. Sessions will be delivered by either 1) a PM+ Helper- initiated phone call or 2) a participant-initiated call via a call-in help line. Airtime will be provided so that participation will be free of charge. Sessions will continue after the birth if not completed during pregnancy. PM+ Helpers will debrief regularly on the progress of participants with clinically trained supervisors - both for their own psychological well-being and to ensure that participants receive adequate care.
BACKGROUND: Tracing patient-specific tumor mutations in cell-free DNA (cfDNA) for minimal residual disease (MRD) detection is promising but challenging. Assaying more mutations and cfDNA stands to improve MRD detection but requires highly accurate, efficient sequencing methods and proper calibration to prevent false detection with bespoke tests.
METHODS: MAESTRO (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides) uses mutation-specific oligonucleotide probes to enrich cfDNA libraries for tumor mutations and enable their accurate detection with minimal sequencing. A new approach, MAESTRO-Pool, which entails pooling MAESTRO probes for all patients and applying these to all samples from all patients, was used to screen for 22 333 tumor mutations from 9 melanoma patients in 98 plasma samples. This enabled quantification of MRD detection in patient-matched samples and false detection in unmatched samples from other patients. To detect MRD, a new dynamic MRD caller was used that computes a probability for MRD detection based on the number of mutations and cfDNA molecules sequenced, thereby calibrating for variations in each bespoke test.
RESULTS: MAESTRO-Pool enabled sensitive detection of MRD down to 0.78 parts per million (ppm), reflecting a 10- to 100-fold improvement over existing tests. Of the 8 MRD positive samples with ultra-low tumor fractions <10 ppm, 7 were either in upward-trend preceding recurrence or downward-trend aligning with response. Of 784 patient-unmatched tests, only one was found as MRD positive (tumor fraction = 2.7 ppm), suggesting high specificity.
CONCLUSIONS: MAESTRO-Pool enables massively parallel, tumor-informed MRD testing with concurrent benchmarking of bespoke MRD tests. Meanwhile, our new MRD caller enables more mutations and cfDNA molecules to be tested without compromising specificity. These improve the ability for detecting traces of MRD from blood.
A developing nervous system is particularly vulnerable to the influence of pathophysiological clues and injuries in the perinatal period. Astrocytes are among the first cells that react to insults against the nervous tissue, the presence of pathogens, misbalance of local tissue homeostasis, and a lack of oxygen and trophic support. Under this background, it remains uncertain if induced astrocyte activation, recognized as astrogliosis, is a friend or foe for progressing neonatal neurodevelopment. Likewise, the state of astrocyte reactivity is considered one of the key factors discriminating between either the initiation of endogenous reparative mechanisms compensating for aberrations in the structures and functions of nervous tissue or the triggering of neurodegeneration. The responses of activated cells are modulated by neighboring neural cells, which exhibit broad immunomodulatory and pro-regenerative properties by secreting a plethora of active compounds (including interleukins and chemokines, neurotrophins, reactive oxygen species, nitric oxide synthase and complement components), which are engaged in cell crosstalk in a paracrine manner. As the developing nervous system is extremely sensitive to the influence of signaling molecules, even subtle changes in the composition or concentration of the cellular secretome can have significant effects on the developing neonatal brain. Thus, modulating the activity of other types of cells and their interactions with overreactive astrocytes might be a promising strategy for controlling neonatal astrogliosis.
FIELD: stomatology. SUBSTANCE: invention concerns joining natural and artificial teeth. Material of invention contains acrylate dental preparations of carbodent or evicrole and polyurethaidiol type based on tetramethylene glycol ether, 4,4- diphenylmethane diisocyanate, and diethylene glycol. Optimum concentration of polyurethaidiol is 20-40 weight parts per 100 weight parts of liquid preparation. Mother mixtures of polyurethaidiol and liquid preparation are stable for at least 6 months under storage and provide joined steel specimens shear strength of order of 10 MPa. EFFECT: improved adhesion characteristics and stability. 1 dwg , 4 tbl
The present invention discloses a traditional Chinese medicine composition for treating posthepatitic fibrosis and cirrhosis due to hepatitis B, which is prepared from the following components, in the weight percentages, 30 to 40 of red sage root, 20 to 30 of astragalus root, 10 to 20 of Chinese caterpillar fungus or cordyceps mycelial, 10 to 20 of flavescent sophora root and 5 to 10 of peach seed. The composition also comprises turtle shell, safflower, angelica, suberect spatholobus stem, common leafflower herb with root, red peony root, ganoderma lucidum, tuckahoe, kudzuvine root and curcuma aromatica salisb in the balancing amount of 10 to 20% of the total weight. The composition can also be made into decoction or extract tablets, and the extract tablets are dried in vacuum during the production. The angelica and the turtle shell are individually processed, and the extract tablets are obtained by the processes of pelletization, tabletting, coating, etc. The present invention solves the problems of the existing medicines, such as multiple auxiliary materials, low active components, poor therapeutic effect, high production cost, etc. The formula of the latest dose-effect relationship has the advantages of advanced technique, fewer medicine auxiliary materials, high effective component content, good therapeutic effect, short therapeutic course without toxic or side effect, low production cost, etc. The composition is broadly suitable for treating posthepatitic fibrosis and cirrhosis due to hepatitis B.
BACKGROUND: High-cost users (HCU) represent important targets for health policy interventions. Sepsis is a life-threatening syndrome that is associated with high morbidity, mortality, and economic costs to the healthcare system. We sought to estimate the effect of sepsis on being a subsequent HCU.
METHODS: Using linked health-administrative databases, we conducted a population-based, propensity score-weighted cohort study of adults who survived a hospitalization in Ontario, Canada between January 2016 and December 2017. Sepsis was identified using a validated algorithm. The primary outcome was being a persistent HCU after hospital discharge (in the top 5% or 1% of total health care spending for 90 consecutive days), and the proportion of follow-up time since discharge as a HCU.
RESULTS: We identified 927,057 hospitalized individuals, of whom 79,065 had sepsis. Individuals who had sepsis were more likely to be a top 5% HCU for 90 consecutive days at any time after discharge compared to those without sepsis (OR 2.24; 95% confidence interval [CI] 2.04-2.46) and spent on average 42.3% of their follow up time as a top 5% HCU compared to 28.9% of time among those without sepsis (RR 1.46; 95% CI 1.45-1.48). Individuals with sepsis were more likely to be a top 1% HCU for 90 consecutive days compared to those without sepsis (10% versus 5.1%, OR 2.05 [95% CI 1.99-2.11]), and spent more time as a top 1% HCU (18.5% of time versus 10.8% of time, RR 1.68 [95% CI 1.65-1.70]).
CONCLUSIONS: The sequelae of sepsis result in higher healthcare costs with important economic implications. After discharge, individuals who experienced sepsis are more likely to be a HCU and spend more time as a HCU compared to individuals who did not experience sepsis during hospitalization.
Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.
Citrus peels contain abundant polyphenols, particularly flavonoids, and have been shown to exert lipid accumulation decreasing ability. In this study, Citrus depressa peel applied to oven drying and extracted with ethanol extract as CDEE to analyze its flavonoids compositions and investigated its effects on a high-fat diet (HFD)-induced obese mice model. CDEE contained several flavonoids such as hesperidin, sinesentin, nobiletin, tangeretin, 5-demethylnobiletin, and 5-demethyltangeretin. The mice fed an HFD, and administration of 2% CDEE to could decrease weight gain, abdominal fat weight, inguinal fat weight, and the adipocyte size, and CDEE also reduced serum total cholesterol (TCHO), triacylglycerol (TG) compared with mice fed only on HFD. CDEE hindered lipid accumulation through a decreased fatty acid synthase (FAS) protein expression via upregulation of the protein expression of AMP-activated protein kinase α (AMPKα). Moreover, CDEE modulated gut microbiota that altered by HFD through an increased abundance of Lactobacillus reuteri compared with the HFD group. The results demonstrated that CDEE helps decrease lipid accumulation through the AMPK pathway, which also indicates a prebiotic-like effect on gut microbiota.
Cohort 4. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
Social determinants of health (SDoH)-the conditions in which people are born, grow, work, live, and age-are key drivers of health and health disparities. Children with medical complexity are particularly at-risk given their high healthcare need and utilization. Although the American Academy of Pediatrics and payers such as the Centers for Medicaid and Medicare Services are now recommending medical providers screen for SDoH at visits, studies have not yet demonstrated the impact of SDoH screening and referral interventions on improving child health and have fallen short of exploring potential mechanisms by which such interventions could improve health outcomes. Children with sickle cell anemia (SCA) are an ideal population in which to study the impact of SDoH interventions given the high prevalence of poverty and unmet material needs among this population and the disease's significant morbidity and mortality. This proposal addresses a timely clinically- and policy-relevant research gap by: (1) implementing a SDoH intervention in two outpatient pediatric hematology clinics and gathering preliminary data to assess its impact on child health; and (2) characterizing the potential mechanisms by which addressing SDoH may lead to improved health outcomes. The research team has developed, tested, and implemented a SDOH intervention (WE CARE) which relies on existing clinical processes to screen for unmet material needs and refer parents to community services; efficacy data demonstrates its positive impact on parental receipt of community resources. The investigators now propose conducting a pragmatic pilot cluster randomized controlled trial (RCT) to examine the implementation of WE CARE as standard of care in two of the four hematology clinics. To preliminarily examine outcomes,100 parents of children with SCA (25 per site) will be recruited and followed for one year in order to explore how addressing unmet social needs within the delivery of medical care may improve healthcare utilization and health outcomes. Given the limitations of applying existing theoretical frameworks to culturally diverse populations such as those with SCA, the investigators will also employ a mixed methods approach to characterizing how SDoH influences disease management processes. The specific aims are to: (1) Implement WE CARE in two pediatric hematology clinics in order to field test key study logistics and understand the facilitators and barriers to implementation and accelerate its adoption; (2) Obtain population-specific empirical estimates of study parameters to plan a large-scale multi-site cluster RCT of WE CARE that will definitely assess its impact on improving health outcomes for children with SCA; and (3) Qualitatively assess possible mechanisms linking SDoH interventions to improved health outcomes. It has significant implications for child health policy and is a critical step in potentially transforming the delivery of healthcare for medically complex children.
1341094 Cosmetic emulsions BEIERSDORF AG 13 May 1971 [15 May 1970] 14756/71 Heading A5B [Also in Divisions B1 and C2] Water-in-oil emulsions, suitable for creams and salves use as emulsifying agent a glycerine ester of wool wax acids (see Division C2). The fatty phase may comprise mineral oils and waxes, vegetable and animal oils, waxes, and synthetic fatty acid esters and alcohols, and the aqueous phase may contain dissolved salts, glycerine, and citric and lactic acids. Wool wax alcohols and oleic acid esters of sorbitan, pentaerythritol and glycerol may also be used as emulsifiers. Examples describe a cream comprising wool wax acids glycerine partial ester, cake paraffin, ozokerite, (R.T.M.) microcrystalline wax, vaseline (R.T.M.), and paraffin oil in the fatty phase and magnesium sulphate, glycerine, water and perfume in the aqueous phase, and a salve base comprising the wool wax acids glycerine partial ester, paraffin wax, vaseline (R.T.M.) and paraffin oil.
A dosage form comprising a gelatin capsule formed with a composite wall and containing a liquid, active agent formulation where the wall comprises a barrier layer formed over the external surface of the gelatin capsule, and expandable layer formed over the barrier layer and a semipermeable layer formed over the expandable layer is described. The dosage forms and methods provide for the conversion of standard gelatin, liquid formulation capsules into controlled, release dosage forms that permit the controlled release of the active agent into the environment of use over time. The gelatin capsule (12) is surrounded by a barrier layer (18), except in the area in which the exit orifice (24) is formed.  Barrier layer (18) is itself surrounded by an expandable layer (20), which is itself surrounded by an external semipermeable layer (22).  An exit orifice (24) is formed through external layer (22), expandable layer (20) and barrier layer (18), but does not extend through the wall of gelatin capsule (12) although it may extend part of the way into the capsule wall.  The exit orifice (24) may be formed as an opening as shown; or, while not shown, exit orifice (24) could be formed of a solid or semi-solid material that will dissolve, leach out, or otherwise provide an opening extending from the environment of use to the wall of the gelatin capsule to permit release of the liquid, active agent formulation when the dosage form is in the environment of use.
Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age. All vaccines were administered intramuscularly in the anterolateral side of the left thigh (Poliorix) and the right thigh (Infanrix).